XTX Topco Ltd Makes New Investment in Bio-Rad Laboratories, Inc. (NYSE:BIO)

XTX Topco Ltd bought a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 1,949 shares of the medical research company's stock, valued at approximately $640,000.

Several other large investors also recently added to or reduced their stakes in BIO. Metis Global Partners LLC increased its stake in shares of Bio-Rad Laboratories by 4.4% in the fourth quarter. Metis Global Partners LLC now owns 712 shares of the medical research company's stock worth $234,000 after acquiring an additional 30 shares during the last quarter. Signaturefd LLC increased its position in Bio-Rad Laboratories by 13.2% during the fourth quarter. Signaturefd LLC now owns 265 shares of the medical research company's stock worth $87,000 after buying an additional 31 shares during the last quarter. UMB Bank n.a. increased its position in Bio-Rad Laboratories by 41.6% during the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock worth $36,000 after buying an additional 32 shares during the last quarter. Thrivent Financial for Lutherans increased its position in Bio-Rad Laboratories by 0.7% during the fourth quarter. Thrivent Financial for Lutherans now owns 4,530 shares of the medical research company's stock worth $1,488,000 after buying an additional 32 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. increased its position in Bio-Rad Laboratories by 3.9% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company's stock worth $296,000 after buying an additional 34 shares during the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

Bio-Rad Laboratories Stock Performance

Shares of NYSE BIO traded up $1.63 during mid-day trading on Thursday, hitting $250.48. The company had a trading volume of 59,292 shares, compared to its average volume of 314,255. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85. The business's 50-day simple moving average is $252.39 and its 200-day simple moving average is $309.79. Bio-Rad Laboratories, Inc. has a 12 month low of $215.38 and a 12 month high of $387.99. The firm has a market cap of $7.02 billion, a P/E ratio of -3.85 and a beta of 1.12.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. As a group, analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BIO has been the topic of several analyst reports. Wells Fargo & Company lowered their target price on shares of Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. StockNews.com downgraded shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $481.00 price target on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $380.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.